Document Detail

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
MedLine Citation:
PMID:  16965950     Owner:  NLM     Status:  MEDLINE    
There are increasing reports of Philadelphia-negative (Ph-negative) clonal hematopoiesis developing among patients with chronic myeloid leukemia (CML) treated with imatinib mesylate (IM). To establish the incidence and significance of these chromosomal abnormalities, we analyzed data on 141 consecutive patients with CML treated with IM at the British Columbia Cancer Agency and Vancouver General Hospital from 1999 to 2004. The cumulative incidence of developing a Ph-negative clone three years from the start of IM was 8.7% at a median of 13.3 months. The Ph-negative clonal abnormalities included monosomy 7 and/or trisomy 8 (seven patients), monosomy for chromosomes X and 22 (one patient), and a (12;16) translocation (one patient). Two of the patients presented with the same chromosomal abnormality in both Ph-negative and Ph-positive cells. None of the Ph-negative clonal abnormalities was associated with myelodysplasia. In a multivariate analysis, an interval from diagnosis to initiation of IM of 1 year or less was associated with an increased risk of developing a Ph-negative clone (relative risk = 20.2; P = 0.025). There was no difference, however, in event-free survival between patients who did and did not develop Ph-negative clones. Therefore, while the development of Ph-negative clonal hematopoiesis in patients with CML treated with IM is uncommon, it appears to be more frequent than that previously seen with IFN, but it does not seem to confer a worse prognosis.
Yulia Lin; Hélène Bruyère; Douglas E Horsman; Tapio Pantzar; Michael J Barnett; Donna E Hogge; Thomas J Nevill; Stephen H Nantel; Heather J Sutherland; Cynthia L Toze; John D Shepherd; Julye C Lavoie; Kevin W Song; Clayton A Smith; Donna L Forrest
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer genetics and cytogenetics     Volume:  170     ISSN:  0165-4608     ISO Abbreviation:  Cancer Genet. Cytogenet.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-12     Completed Date:  2006-10-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7909240     Medline TA:  Cancer Genet Cytogenet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16-23     Citation Subset:  IM    
The Leukemia/BMT Program of British Columbia, the Division of Hematology, 950 West 10th Avenue, Room 3300, Vancouver, British Columbia V5Z 4E3, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  genetics*
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / drug therapy*,  genetics*
Middle Aged
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Risk Factors
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cytogenetic and molecular genetic changes in malignant mesothelioma.
Next Document:  KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural ste...